A comparative cost-effectiveness analysis of mechanical and pharmacological VTE prophylaxis after lower limb arthroplasty in Australia
Journal of Orthopaedic Surgery and Research Apr 09, 2019
Torres RT, et al. - In this study, authors examined the cost and quality-adjusted life years (QALYs) saved of commonly used venous thromboembolism (VTE) prophylaxis regimens following lower limb arthroplasty. They observed a range of costs from AUD $644 (IPC) to AUD $956 (rivaroxaban) for VTE prophylaxis including treatment of its correlated complications over the first year after surgery. Intermittent pneumatic compression (IPC) was the cheapest measure in 73% of simulations across 500 simulations. An association of DOAC with the highest resulting QALYs was observed in 97% of simulations. They found apixaban cost-effective in 76.4% of simulations and apixaban plus IPC in 87.8% of simulations when compared to IPC. They overall suggested apixaban, IPC or a sequential/simultaneous combination of both the most cost-effective VTE prophylaxis regimens. They also suggested choosing the regimen by the relative VTE and bleeding risks of an individual case.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries